CRISM Therapeutics appeared among the most volatile UK stocks on 23 September 2026. The AIM-quoted cancer drug-delivery company has just opened recruitment for a Phase 2 glioblastoma trial and published interim results. It is trading close to the 10p price of its May placing.

CRISM Therapeutics (LSE:CRTX) was among the most volatile UK stocks on 23 September 2026. The company is a clinical-stage drug-delivery Business developing ChemoSeed, a biodegradable implant that releases chemotherapy directly into tumour tissue. Its lead target is glioblastoma, an aggressive brain cancer.

CRISM is quoted on AIM, where it was admitted in May 2024, and its Market Value is under £10m. In the past few weeks it has announced patient recruitment for its first clinical trial, published half-year results on 21 September and appointed a new chair. Investors may be paying attention to how a small, cash-limited biotech manages its first clinical milestones.

Why CRISM Therapeutics (CRTX) Is in Focus

On 23 September 2026 the shares last traded at 9.75p. The shares were down 12.44% over the week, around 15% over one month and about 17% over six months, but roughly flat over one year. Daily Volatility was 5.26%, with a Market Capitalisation of about £7.7m.

That combination suggests an active news flow. There have been big moves within the year, but they have not added up to a clear long-term trend.

What Does CRISM Therapeutics Do?

ChemoSeed is designed to be implanted during surgery, either into a tumour or into the Margin left after a tumour is removed. It delivers sustained, local doses of chemotherapy drugs that are already approved, such as irinotecan. In glioblastoma, the company says this approach bypasses the blood-brain barrier, which limits many treatments.

CRISM describes ChemoSeed as a potential platform technology. Its second programme, docetaxel-ChemoSeed, targets prostate cancer. Much of its work is outsourced, including clinical research through an outsourced clinical research partner.

What Has Been Happening Recently?

On 17 March 2026 the company announced that the US Food and Drug Administration had granted Orphan Drug designation for irinotecan-ChemoSeed. It released positive preclinical prostate cancer data on 21 April.

On 26 May CRISM raised £2.5m through a placing at 10p per share, with one Warrant attached for each share, exercisable at 15p until 16 December 2027. A retail offer brought the total to £2.745m. Grants from Innovate UK (£896,088) and Invest Northern Ireland (£99,902) were announced in early June.

The clinical programme then advanced. The site initiation visit at University Hospitals Birmingham NHS Foundation Trust was completed on 13 August, and on 20 August the company said the site had been activated and recruitment had started. On 17 September it named Charles Spicer as non-executive chair from 1 October, and interim results followed on 21 September.

What Are the Numbers Saying?

For the six months to 30 June 2026, CRISM reported a loss of £1.413m (H1 2025: £0.93m). Administrative expenses were £1.52m, including Research and Development spending of £956,000. As a pre-revenue company, it reported no revenue.

The company gave net cash of £1.9m at 18 September 2026. It says the May fundraise and grant funding "provide a clear runway" to execute its Phase 2 milestones in glioblastoma, and it continues to look for further non-dilutive funding. The placing shares represented about 32.6% of the enlarged share capital, showing how much dilution the fundraise involved.

Why Is the Share Price Attracting Attention?

Facts: the shares trade just below the 10p placing price and well below the 15p warrant exercise price. Patient recruitment has begun, but the first patient had not been treated as at the interim report, which said dosing was "expected shortly".

Possible interpretations: one possible interpretation is that investors are trading around binary clinical milestones, which is common for early-stage biotechs. Some investors may view the placing price as a reference point. Others may weigh the modest cash balance against the cost of a two-part trial. A small market value and limited Liquidity can magnify these reactions. Volatility describes past swings, not future direction.

How Does the FTSE AIM All-Share Context Matter?

CRISM is quoted on AIM, and FTSE AIM All-Share membership has not been verified. Small AIM life-sciences companies often depend on periodic Equity raises and grants, and their shares tend to react to financing terms and trial news more than to wider market movements.

There is no evidence that moves in the wider AIM market caused CRISM's recent swings. Its own announcements over August and September provide a more direct explanation for the attention.

What Could Investors Watch Next?

Milestones flagged by the company include:

  • First patient dosed: the company has said it will update the market once the first patient has been treated with ChemoSeed.
  • Part 1 progress: dose escalation in recurrent glioblastoma, ahead of Part 2, which will assess progression-free survival in newly diagnosed patients.
  • Prostate programme: preclinical and regulatory work on docetaxel-ChemoSeed supported by the Invest NI grant.
  • Funding: further grant awards, cash use against the £1.9m balance and any warrant exercises.
  • Intellectual property: Patent progress in the US and China, following grants in the EU and Japan.

The Bottom Line

CRISM Therapeutics appeared among the most volatile UK stocks as it moved from preclinical work into a registration-grade Phase 2 trial. Recruitment opened in August at a Birmingham NHS site. The company has FDA orphan drug designation for irinotecan-ChemoSeed, a £2.745m fundraise completed in May and two new grants. Its shares have nonetheless fallen back to just under the 10p placing price, and its net cash stood at £1.9m in September. What matters next is treatment of the first patient, progress through Part 1 of the trial and how the company funds its clinical programme.